Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Encompass Health Corporation’s (NYSE: EHC) SEC filings, offering detailed insight into the company’s inpatient rehabilitation hospital business and financial profile. As the largest owner and operator of inpatient rehabilitation hospitals in the United States, Encompass Health uses its filings to report operating results, liquidity measures and other material information.
Current reports on Form 8-K included in the available information show how the company discloses quarterly financial results, updates to full-year guidance and investor materials. These filings reference metrics such as net operating revenue, Adjusted EBITDA, adjusted earnings per share, leverage ratio and adjusted free cash flow, along with explanations of why non-GAAP measures are used and how they are reconciled to comparable GAAP figures.
Other 8-K filings address topics like publication of an Investor Reference Book, which provides an overview of the company and its industry, business outlook, growth strategy and operational initiatives, as well as Regulation FD communications when senior management meets with investors and analysts. Governance-related 8-Ks can also appear, such as notices of director departures.
Through this filings page, users can review Encompass Health’s earnings-related 8-Ks, Regulation FD disclosures and other material event reports as they are made available via EDGAR. AI-powered tools on the platform can help summarize lengthy documents, highlight key metrics and clarify definitions of non-GAAP measures like Adjusted EBITDA and adjusted free cash flow, making it easier to understand how the company evaluates performance, manages leverage and plans for growth.
For anyone analyzing EHC stock, these SEC filings are a primary source for understanding Encompass Health’s financial condition, risk disclosures, capital structure and strategic communications with investors.
Encompass Health Corporation reported strong first-quarter 2026 growth, with net operating revenues of $1,586.6 million, up 9.0% from $1,455.4 million a year earlier, driven by higher patient volumes and improved pricing.
Net income attributable to Encompass Health rose to $194.5 million from $151.5 million, and diluted EPS increased to $1.93 from $1.48. Adjusted EBITDA reached $348.8 million versus $313.6 million. Cash from operating activities was $313.1 million, supporting continued hospital expansion, dividends, and share repurchases while managing long-term debt maturities beginning in 2028.
Encompass Health Corporation reported strong first-quarter 2026 results and raised its full-year outlook. Net operating revenue grew 9.0% to $1,586.6 million, driven by 4.3% higher discharges and a 3.7% increase in net patient revenue per discharge to $22,633.
Adjusted EBITDA rose 11.2% to $348.8 million, while diluted earnings per share from continuing operations increased to $1.77, with adjusted earnings per share up 16.8% to $1.60. Adjusted free cash flow was $193.8 million, down from $222.4 million a year earlier, reflecting higher maintenance capital spending and distributions to noncontrolling interests.
The company continued to expand capacity, opening a new 49-bed hospital in Irmo, South Carolina and adding 44 beds at existing facilities. It amended and restated its credit agreement, extending maturity to March 2031, and reported net leverage of 1.9x. Encompass Health repurchased 707,965 shares for $71.6 million and paid a quarterly dividend of $0.19 per share.
For full-year 2026, management modestly increased guidance, now expecting net operating revenue of $6,375 million to $6,470 million, Adjusted EBITDA of $1,350 million to $1,380 million, and adjusted earnings per share from continuing operations of $5.89 to $6.11.
Encompass Health Corp reports beneficial ownership of 5,233,622 shares of Common Stock, representing 5.26% of the class as of 03/31/2026. The filing attributes sole voting power for 767,385 shares and sole dispositive power over 5,233,622 shares to Vanguard Capital Management and certain affiliates under SEC Release No. 34-39538.
Encompass Health Corp passive ownership disclosure: Vanguard Portfolio Management reported beneficial ownership of 4,971,601 shares, representing 5% of common stock.
The filing states Vanguard has sole voting power for 12,056 shares and sole dispositive power for 4,971,601 shares. The report is signed by Ashley Grim on 04/29/2026.
CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Greg D. Carmichael received additional stock-based compensation through a routine dividend-related award. On April 15, 2026, he was granted 27 restricted stock units (RSUs) of Encompass Health Common Stock at no cash cost, increasing his direct holdings to 18,686 shares.
The footnote explains that, under outstanding RSU award agreements, extra RSUs are credited to each non-employee director when common stock dividends are paid. The number of RSUs is based on the existing RSU balance, the per share dividend of $0.19, and the $105.24 closing price on the dividend payment date.
Encompass Health Corp director Edward M. Christie III reported acquiring additional common stock through compensation-related programs. On April 16, he received 261 shares at a weighted average price of $106.17 per share, tied to restricted stock units that accrue additional units when common stock dividends are paid.
The RSU credit was based on a $0.19 per share dividend paid on April 15 and a closing price of $105.24 on that date. He also acquired 9 shares on April 15 through the Directors Deferred Stock Investment Plan, where deferred director fees and associated dividends are used to purchase Encompass Health common stock in the market. Following these awards, he directly holds 7,452 shares of Encompass Health common stock.
Hayes Cain A reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Hayes Cain A received an automatic award of 1 restricted stock unit linked to a common stock dividend. This award arose under outstanding RSU agreements when Encompass Health paid a $0.19 per share dividend and the stock closed at $105.24 on April 15, 2026. Following this grant, Cain directly holds 458 shares or units of Encompass Health common stock.
Encompass Health Corp director Joan E. Herman received an automatic share-based award tied to a dividend payment. On April 15, 2026, she acquired 85 Encompass Health common stock equivalent restricted stock units at no cash cost, credited under existing RSU agreements in connection with a $0.19 per share dividend and a $105.24 closing price. Following this grant, she directly holds 47,924 shares of Encompass Health common stock.
Encompass Health Corp director Leslye G. Katz received an equity award tied to a dividend reinvestment feature. On April 15, 2026, she acquired 85 restricted stock units (RSUs) for Encompass Health common stock at no cost, credited in connection with a $0.19 per share dividend and a $105.24 closing price. Following this routine compensation-related award, she directly holds 47,924 shares of Encompass Health common stock.
Encompass Health Corp director Kevin J. O’Connor reported a small compensation-related equity award. On April 15, 2026, he acquired 17 Encompass Health common stock restricted stock units credited in connection with a common stock dividend. These units were valued using the $105.24 closing price on the dividend payment date. Following this award, his directly held Encompass Health common stock position stands at 9,929 shares.